← Leaderboards
Raymond B Birge
Rutgers Biomedical And Health Sciences
$4,162,311
Attributed
$5,116,768
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $508.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,116,768 · 4
By mechanism
R01$4,708,831 · 3
R21$407,937 · 1
Top collaborators
- Sergei V Kotenko4 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Dongfang Liu$7,090,729
- Xiaofeng Steven Zheng$14,999,123
- Sergei V Kotenko$7,576,497
- Pingping Hou$2,730,524
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsCellsPhosphorylationMediatingMouse ModelProtein Tyrosine KinaseMalignant Breast NeoplasmSignal TransductionProteinsReceptor Protein-Tyrosine KinasesApoptoticIn VivoMalignant NeoplasmsNeoplasm MetastasisBiologyTriple-Negative Invasive Breast CarcinomaProtein BindingTherapeutic TargetBaseAdenocarcinomaCis Trans IsomerizationCell MotilityBehaviorAffinity
Grant awards (19)
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$473,506
R01 · FY2025 · CA · contact PI
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$453,632
R01 · FY2024 · CA · contact PI
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$473,620
R01 · FY2023 · CA · contact PI
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$508,157
R01 · FY2022 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$329,925
R01 · FY2016 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$13,955
R01 · FY2016 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$329,925
R01 · FY2015 · CA · contact PI
Non-canonical Signal Pathway for Crk in Breast Cancer$85,676
R01 · FY2015 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$320,027
R01 · FY2014 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$278,781
R01 · FY2013 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$55,994
R01 · FY2013 · CA · contact PI
Non-canonical signal pathway for Crk in breast cancer$323,700
R01 · FY2012 · CA · contact PI
Targeting FKBP52 and Copper in Alzheimer's Disease$216,672
R21 · FY2007 · AG · contact PI
Targeting FKBP52 and Copper in Alzheimer's Disease$191,265
R21 · FY2006 · AG · contact PI
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF$276,383
R01 · FY2003 · GM
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF$268,423
R01 · FY2002 · GM
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF$266,507
R01 · FY2001 · GM
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF$153,750
R01 · FY2000 · GM
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF$96,870
R01 · FY2000 · GM